全文获取类型
收费全文 | 179篇 |
免费 | 8篇 |
专业分类
妇产科学 | 12篇 |
基础医学 | 9篇 |
临床医学 | 3篇 |
内科学 | 68篇 |
特种医学 | 1篇 |
外科学 | 56篇 |
综合类 | 1篇 |
药学 | 4篇 |
肿瘤学 | 33篇 |
出版年
2023年 | 1篇 |
2022年 | 3篇 |
2021年 | 4篇 |
2020年 | 7篇 |
2019年 | 6篇 |
2018年 | 10篇 |
2017年 | 6篇 |
2016年 | 6篇 |
2015年 | 2篇 |
2014年 | 7篇 |
2013年 | 9篇 |
2012年 | 8篇 |
2011年 | 11篇 |
2010年 | 9篇 |
2009年 | 11篇 |
2008年 | 13篇 |
2007年 | 8篇 |
2006年 | 6篇 |
2005年 | 5篇 |
2004年 | 9篇 |
2003年 | 13篇 |
2002年 | 6篇 |
2001年 | 8篇 |
2000年 | 5篇 |
1999年 | 3篇 |
1998年 | 1篇 |
1997年 | 4篇 |
1996年 | 1篇 |
1995年 | 3篇 |
1992年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有187条查询结果,搜索用时 31 毫秒
1.
2.
3.
Ran Oren Gershom Zajicek Yoram Maaravi Gabriel Kenet Fanny Karmely Ayala Hubert Pia Raanani Nadir Arber 《Digestive diseases and sciences》1997,42(7):1433-1437
Hepatocytes are hypothesized to continuallystream from the portal tract to the terminal hepaticvein. By this model, when a cell divides, one of itsprogeny replaces the dividing ancestor and the other is displaced into a more remote location. Thepresent experiment aims to demonstrate thathypothyroidism affects liver cell turnover. Thirty maleadult rats were divided into two groups. One receivedmethimazole for two weeks and the other served as control.Each rat was injected intraperitoneally with 18.5 KBq[3H]thymidine/g body weight. Rats were killedafter 1 hr and two and four weeks. Autoradiography was done. The distance of the labeled cells fromthe portal tract was measured. The mean TSH levels ofthe methimazole-treated group and controls were 1.45 and0.25 mM/liter, respectively (P < 0.01). Hepatocyte streaming was lower in hypothyroid (1.8m/day) than in untreated rats (2.5 m/day) (P< 0.01). The respective labeling indices 1 hr afterlabeling were 0.9% and 1.24% (P < 0.05). We concludethat hypothyroidism diminishes hepatocyte and littoral cellturnover and slows down their streaming. 相似文献
4.
Livneh Nir Braeken Dionne Drozdinsky Genady Gafter-Gvili Anat Seelig Jaap Rozovski Uri Berger Tamar Raanani Pia Falanga Anna ten Cate Hugo Spectre Galia Leader Avi 《Journal of thrombosis and thrombolysis》2021,52(2):590-596
Journal of Thrombosis and Thrombolysis - Managing anticoagulation in hematological malignancy patients with atrial fibrillation and thrombocytopenia is a clinical challenge with limited data. We... 相似文献
5.
Meirow D Dor J Kaufman B Shrim A Rabinovici J Schiff E Raanani H Levron J Fridman E 《Human reproduction (Oxford, England)》2007,22(6):1626-1633
BACKGROUND: Chemotherapy destroys primordial follicles and can lead to ovarian atrophy. Although reports indicate that apoptosis is the mechanism responsible for follicle loss, additional pathways can be involved. This study investigates the damage in human ovaries after administration of non-sterilizing doses of chemotherapy. METHODS: In a blind study, pathological changes in ovarian tissue harvested for cryopreservation were evaluated. The study group comprised young non-sterile cancer patients, previously exposed to chemotherapy who were (mean +/- SD), when compared with non-exposed patients. RESULTS: Thirty-five cancer patients aged 28.7 +/- 6.74; 17 were previously exposed to non-sterilizing chemotherapy and 18 were not. In all samples, primordial follicles were present. In previously exposed patients, damage to cortical blood vessel and proliferation of small vessels was observed. The cortex showed focal areas of fibrosis with disappearance of follicles (sensitivity 76%, positive predictive value 75% for <37 years old patients). Older patients, not exposed to chemotherapy (5/7) showed similar pathological changes. CONCLUSIONS: Injury to blood vessels and focal ovarian cortical fibrosis are aspects of ovarian damage caused by chemotherapy. These findings indicate a potential additional mechanism of damage to the direct apoptotic effect of chemotherapy on follicles. The possibility that these changes are involved in ageing ovaries should be further investigated. 相似文献
6.
7.
8.
9.
Ofer Shpilberg Nuhad Haddad Orit Sofer Pia Raanani Miriam Berkowicz Angela Chetrit Anna Carter Bracha Ramot Ilana Tatarski Isaac Ben-Bassat 《Leukemia research》1995,19(12):893-897
Sixty-seven out of 105 (64%) adults with de novo acute myelogenous leukemia (AML), achieving complete remission after induction chemotherapy, entered two successive postremission treatment protocols. Between 1987 and 1989, 35 patients received an intermediate dose of cytarabine (IDAC) along with other drugs. Between 1990 and 1993, 32 patients received high dose cytarabine (HIDAC) with similar other drugs. Patients treated with IDAC had a median survival of 13.8 months (95% Cl 11.2–23.1 months) and a 2 year survival of 34.3 ± 8.0%. Patients receiving HIDAC had a median survival of 35.5 months (95% Cl, lower limit 29.8 months) and a 2 year survival of 71.6 ± 9.4% (P < 0.002). The 2 year actuarial leukemia-free survival (LFS) was 17.8 ± 6.6% in the IDAC group and 67.3 ± 10.0% months in the HIDAC group (P = 0.004). The HIDAC group had a significant 2 year survival advantage over the IDAC group only in patients younger than 45 years. The 2 year survival in the first group was 83.3 ± 10.8% versus 23.5 ± 10.3% in the IDAC group (P = 0.0001). In patients older than 45 years, no significant differences in 2 year survival was noticed (52.9 ± 15.78 versus 44.4 ± 11.7, P = 0.8). Censoring the 21 patients who underwent bone marrow transplantation (BMT) at BMT did not change significantly the survival analysis of the patients in each group. This study is consistent with previous reports favoring HIDAC intensification in the postremission treatment of young patients with AML. 相似文献
10.
The hematological malignancies associated with nephrotic syndrome are mainly Hodgkin's and non-Hodgkin's lymphomas and chronic lymphocytic leukemia. Acute myelogenous leukemia (AML) has rarely been described in association with the nephrotic syndrome. The clinical course of a 44-year-old patient with AML who presented with nephrotic syndrome is described and the clinicopathologic features of the other cases reported in the world literature are reviewed. We could not find a consistent pattern regarding the subtype of leukemia, renal pathology, and temporal relationship between the nephrotic syndrome and the leukemia or the response to treatment. The present case was unique in that the clinical course of the renal disorder correlated with the course of the leukemia responding to treatment with anti-leukemic agents. We conclude that nephrotic syndrome can also be associated with AML. In some cases there is a direct causal effect of the leukemic process on the renal pathology while in others it is exerted indirectly via other complications of the malignancy or the treatment. 相似文献